CA Patent

CA3000306A1 — Compositions including meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain

Assigned to Individual · Expires 2017-03-16 · 9y expired

What this patent protects

The present invention is directed to a method of administering a meloxicam formulation to a mammalian subject in need thereof including: orally administering to the subject an oral solid dosage form including an amorphous meloxicam-cyclodextrin inclusion complex, where administer…

USPTO Abstract

The present invention is directed to a method of administering a meloxicam formulation to a mammalian subject in need thereof including: orally administering to the subject an oral solid dosage form including an amorphous meloxicam-cyclodextrin inclusion complex, where administering the amorphous meloxicam-cyclodextrin inclusion complex results in the subject achieving a Tmax not greater than about 3.0 hours.

Drugs covered by this patent

Patent Metadata

Patent number
CA3000306A1
Jurisdiction
CA
Classification
—
Expires
2017-03-16
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.